ReviewImmunologic research2010
Tumor-mediated inhibition of dendritic cell differentiation is mediated by down regulation of protein kinase C beta II expression.
Review in Immunologic research, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 27 citations in OpenAlex.
- β-Glucosylceramides and Tocopherols Regulate Development and Function of Dendritic Cells.Journal of immunology (Baltimore, Md. : 1950) · 2022Article
- Asthma, allergy and vitamin E: Current and future perspectives.Free radical biology & medicine · 2022Article
- PTBP1 is necessary for dendritic cells to regulate T-cell homeostasis and antitumour immunity.Immunology · 2021Article
- Extracellular Vesicles in Reprogramming of the Ewing Sarcoma Tumor Microenvironment.Frontiers in cell and developmental biology · 2021Review
- An Immune-Related Gene Pairs Signature for Predicting Survival in Glioblastoma.Frontiers in oncology · 2021Article
- Current challenges for cancer vaccine adjuvant development.Expert review of vaccines · 2018Review
- Oxidative Stress: Harms and Benefits for Human Health.Oxidative medicine and cellular longevity · 2017Review
- Signal transducer and activator of transcription 3 in myeloid-derived suppressor cells: an opportunity for cancer therapy.Oncotarget · 2016Review
- The immunobiology of myeloid-derived suppressor cells in cancer.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2016Review
- Myeloid-derived suppressor cells in B cell malignancies.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2015Review
- Myeloid-Derived Suppressor Cells: Critical Cells Driving Immune Suppression in the Tumor Microenvironment.Advances in cancer research · 2015Review
- Pathological mobilization and activities of dendritic cells in tumor-bearing hosts: challenges and opportunities for immunotherapy of cancer.Frontiers in immunology · 2013Review
- Melanoma-infiltrating dendritic cells: Limitations and opportunities of mouse models.Oncoimmunology · 2012Article
- Coordinated regulation of myeloid cells by tumours.Nature reviews. Immunology · 2012Review
- Protein kinase C signaling and cell cycle regulation.Frontiers in immunology · 2012Article
- Molecular mechanisms regulating myeloid-derived suppressor cell differentiation and function.Trends in immunology · 2011Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Tumor-mediated immune suppression occurs through multiple mechanisms, including dysregulation of dendritic cell differentiation. This block in differentiation results in fewer dendritic cells and an accumulation of immunosuppressive myeloid- derived suppressor cells and is thought to contribute to tumor outgrowth and to act as an impediment to successful anti-cancer immunotherapy. Tumor-mediated myeloid dysregulation is known to be Stat3 dependent; however, the molecular mechanism of this Stat3 signaling remains poorly defined. We have previously shown that PKC betaII is required for dendritic cell differentiation. Here, we describe our finding that tumors mediate both Stat3 activation and PKC betaII down regulation in DC progenitor cells, a process mimicked by the expression of a constitutive active Stat3 mutant. This demonstrates that tumor-mediated myeloid dysregulation may be mediated by Stat3- induced PKC betaII down regulation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.